文献速递牙体牙髓病

新型Endosequence BC Sealer HiFlow的化学成分与生物活性潜力

Chemical composition and bioactivity potential of the new Endosequence BC Sealer formulation HiFlow.
PubMed 文献 · Int Endod J · 2020-06-18

该实验室研究评估了新型硅酸钙基根管封闭剂Endosequence BC Sealer HiFlow(BCHiF)对人牙周膜干细胞(hPDLSCs)的影响。通过SEM-EDX、ICP-MS、MTT、伤口愈合、SEM、茜素红及qPCR等方法,并与BCS和AH Plus对比。结果显示BCHiF具有适宜的生物学特性,能促进hPDLSCs的成骨/成牙骨质基因表达,可安全用作根管充填材料。

要点

  • BCHiF的锆含量显著高于BCS(P<0.05),而BCS的Ca2+水平略高于BCHiF(P<0.05)。
  • BCHiF与BCS在细胞活力、迁移、形态和黏附方面与对照组无显著差异,而AH Plus组黏附能力降低。
  • BCHiF和BCS均促进hPDLSCs的成骨/成牙骨质基因过表达,茜素红染色与对照组有显著差异(P<0.001)。

核心结论

  • EndoSequence BC Sealer HiFlow总体上具有适宜的生物学特性,可安全用作根管充填材料,并促进hPDLSCs的成骨/成牙骨质基因表达。

研究设计与样本

  • 实验室研究,将BCHiF、BCS和AH Plus的洗脱液与hPDLSCs接触。
  • 采用SEM-EDX分析化学元素,ICP-MS测定离子释放,MTT和伤口愈合法检测细胞活力和迁移。
  • 通过直接接触技术和SEM评估细胞形态与黏附,茜素红和qPCR检测生物活性潜力。
  • 统计采用单因素方差分析和Tukey检验(P<0.05)。

主要发现

  • ICP-MS和EDX显示BCHiF的锆含量显著高于BCS(P<0.05),BCS的Ca2+水平略高于BCHiF(P<0.05)。
  • 细胞活力 assay 显示BCS和BCHiF与对照组相比无相关差异(P>0.05)。
  • BCS和BCHiF在24和48小时的细胞迁移率与对照组相似。
  • BCS和BCHiF组的细胞形态和黏附能力相似,而AHP组黏附能力降低。
  • 茜素红 assay 显示BCS与对照组有显著差异(P<0.001),BCHiF组与对照组也有显著差异(P<0.001)。

临床怎么用

  • BCHiF具有适宜的生物学特性,可安全用于根管充填,尤其适用于热牙胶充填技术。
  • BCHiF能促进hPDLSCs的成骨/成牙骨质基因表达,可能有利于根尖周组织修复。

局限性

  • 研究为实验室体外研究,结果需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate in a laboratory setting the effects of Endosequence BC Sealer HiFlow (Brasseler USA, Savannah, GA, USA), a novel calcium silicate-based sealer developed for use in warm canal filling techniques, on human periodontal ligament stem cells (hPDLSCs). METHODOLOGY: Eluates of EndoSequence BC Sealer HiFlow (BCHiF) (Brasseler USA), EndoSequence BC Sealer (BCS) (Brasseler USA) and AH Plus (AHP) (Dentsply DeTrey GmbH, Konstanz, Germany) were placed in contact with hPDLSCs. The characterization of the chemical elements of the root canal sealers was assessed using scanning electron microscopy and energy-dispersive X-ray analysis (SEM-EDX). Inductively coupled plasma-mass spectrometry (ICP-MS) was used to determine the ion release of the sealers. MTT assay and wound healing techniques were used to determine cell viability and migration, respectively. Cell morphology and cell attachment were assessed using a direct contact technique of hPDLSCs onto the surface of the sealers and analysed by SEM. The bioactivity potential was carried out with the Alizarin Red and qPCR testing methods. The statistical differences were evaluated using one-way anova and Tukey's test (P < 0.05). RESULTS: ICP-MS and EDX revealed significantly more zirconium in BCHiF than BCS (P < 0.05), whereas BCS had slightly higher levels of Ca2+ than BCHiF (P < 0.05). The cell viability assay revealed no relevant differences between BCS and BCHiF when compared with the control group (P > 0.05). Both BCS and BCHiF had similar rates of cell migration to the control group at 24 and 48 h. Cell morphology and adhesion capacity were also similar for BCS and BCHiF groups, whilst the AHP group was associated with reduced adhesion capacity. The Alizarin Red assay revealed a significant difference between the BCS and the control group (P < 0.001), as well as for the BCHiF group (P < 0.001). Finally, BCS and BCHiF promoted overexpression of osteo/cementogenic genes. CONCLUSIONS: In general, EndoSequence BC Sealer HiFlow possesses suitable biological properties to be safely used as a root canal filling material and promote increased expression of oste/cementogenic genes by hPDLSCs.

来源:Int Endod J,查看原文。版权归原作者所有。

引用

  1. Rodríguez-Lozano FJ, López-García S, García-Bernal D, et al. Chemical composition and bioactivity potential of the new Endosequence BC Sealer formulation HiFlow. Int Endod J. 2020. PMID: 32412113. doi:10.1111/iej.13327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。